![]() Currently, there are no FDA approved pharmaceutical treatments available for presbyopia. ![]() Although there are a number of approaches to managing the visual disability associated with presbyopia, all of the currently available treatments are compensatory rather than corrective. An estimated 1.8 billion people worldwide have presbyopia, including over 110 million in the US alone. Presbyopia can have multiple effects on quality of vision and quality of life and if uncorrected, results in an inability to perform once‐effortless tasks at a customary working distance without experiencing visual symptoms. Presbyopia is the most prevalent eye condition in the United States and by age 45, has often advanced to the point where some type of optical correction, such as reading glasses or bifocals, is required. ![]() Presbyopia is the natural, gradual loss of the eye's ability to focus on nearby objects. Hollander, MD, MBA, Chief Medical Officer at Ora commented, "This presbyopia treatment showed a sustained three line improvement in near visual acuity. This medication has the advantage of a very quick onset – within 30 minutes of instillation. PRX may offer a much-needed alternative to spectacles, contact lenses and surgery for the growing worldwide presbyopic population." The study was conducted by Ora, Inc. ( Andover, MA. A total of 58 subjects participated in the study. At one hour after instillation, 47.2% of study eyes gained at least three lines (p<0.001) and 91.7% gained at least two lines of improvement in near vision (p<0.0001). Approximately one half of study eyes maintained a two line or greater improvement up to seven hours. This unique drug was well-tolerated, with no significant loss in monocular best corrected distance visual acuity in study eyes, and no serious adverse events. This Phase IIb randomized, double-masked, placebo controlled study evaluated two unique miotic based test candidates of PRX versus placebo for the treatment of presbyopia. These data warrant rapid future clinical advancement." "PRX demonstrated a statistically significant and clinically meaningful improvement in near visual function within 30 minutes. ![]() PRX has the potential to address a massive unmet need by restoring near vision," said Gerald Horn, MD, Chief Scientific Officer of Presbyopia Therapies. It is estimated that approximately 1.8 billion people globally have presbyopia, including over 110 million in the US alone. "We are thrilled by the positive safety and efficacy outcomes observed throughout this well-controlled, randomized trial. PRX demonstrated a three line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improvement observed in some patients for up to seven hours. Therapist Aid has obtained permission to post the copyright protected works of other professionals in the community and has recognized the contributions from each author.CORONADO, Calif., J/PRNewswire/ - Presbyopia Therapies, LLC, a privately-held ophthalmic pharmaceutical company dedicated to developing therapies for the treatment of presbyopia, today announced that the primary efficacy and safety endpoints have been met in a Phase IIb study of its PRX ophthalmic solution. For more information about how our resources may or may not be used, see our help page. Anyone who violates the exclusive rights of the copyright owner is an infringer of the copyrights in violation of the US Copyright Act. Therapist Aid has the exclusive right to reproduce their original works, prepare derivative works, distribute copies of the works, and in the case of videos/sound recordings perform or display the work publicly. These tools are intended to supplement treatment, and are not a replacement for appropriate training.Ĭopyright Notice: Therapist Aid LLC is the owner of the copyright for this website and all original materials/works that are included. Professionals who use the tools available on this website should not practice outside of their own areas of competency. Disclaimer: The resources available on Therapist Aid do not replace therapy, and are intended to be used by qualified professionals.
0 Comments
Leave a Reply. |